Roche

National Institute for Health and Clinical Excellence
Royal College of General Practitioners
30 Euston Square
London, NW1 2BF

BY EMAIL

6 June 2013

RE: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people [ID373]

Dear Jeremy,

Thank you for giving us the opportunity to comment on the assessment report for the Multiple Technology Appraisal mentioned above. In general, we agree with the Assessment Group's critique of the economic models.

We confirm that peginterferon alpha-2a in combination with ribavirin is now authorized for the treatment of chronic hepatitis C in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA.

We disagree with the comments made in the Implications for service provision described on page 13 of the Assessment Report. We believe requiring expertise in paediatrics should not be weighted so heavily against the general expertise in managing hepatitis C. Children should have the option to be treated in centres beyond the 3 specialised paediatric hepatology centres. This would allow children and their mothers to be seen by the same specialists and maintain their continuum of care.

If any clarification or further analyses would aid the Committee in their deliberations we would be more than happy to provide it.

Y

I [redacted] gic Pricing

Roche Products Limited

6 Falcon Way
Shire Park
Welwyn Garden City
Hertfordshire, AL7 1TW
Registered in England No.100674

Health Economics and Strate
Pricing
Bldg/Room 02-N36